Summary Safety Review - Celecoxib - Assessing the Risk of Serious Heart and Stroke Side Effects at High Doses Relative to Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Health Canada carried out a safety review of all the available evidence to evaluate the risk of side effects related to heart and stroke linked with celecoxib, in comparison to other NSAIDs (diclofenac, ibuprofen, naproxen).

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 22:04 (UTC)
Created April 17, 2026, 22:04 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2017-05-18 00:00:00
open_canada_keywords {"fr": ["Résumé de l'examen de l'innocuité", "célécoxib", "examen de l'innocuité", "évaluation", "accidents vasculaires cérébraux", "effets secondaires", "doses élevées", "anti-inflammatoires non stéroïdiens", "AINS", "diclofénac", "ibuprofène", "naproxène"], "en": ["Summary Safety Review", "Celecoxib", "safety review", "assessing", "heart-and-stroke", "side effects", "high doses", "Non-Steroidal Anti-Inflammatory Drugs", "NSAIDs", "diclofenac", "ibuprofen", "naproxen"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Résumé de l'examen de l'innocuité - Célécoxib (CELEBREX et génériques) - Évaluation du risque d'effets secondaires graves (troubles cardiaques et accident vasculaire cérébral (AVC)) à doses élevées relativement à d'autres médicaments anti-inflammatoires non stéroïdiens (AINS)
update_frequency as_needed